Last reviewed · How we verify
NCT06740097: ATM GBM INT
Feasibility of Aspirate Tissue Monitoring in Neuro-oncological Surgery
NA trial testing Aspirate tissue monitoring in High Grade Gliomas in 50 participants. Currently enrolling.
1 September 2028
Quick facts
| Lead sponsor | Kuopio University Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 30 September 2024 |
| Primary completion | 1 September 2028 |
| Estimated completion | 1 September 2028 |
| Sites | 3 locations across Finland, Norway |
Drugs / interventions tested
- Aspirate tissue monitoring
- Fluorescence-guided surgery
Conditions studied
- High Grade Gliomas — all drugs for High Grade Gliomas →
Sponsor
Kuopio University Hospital
Who can join
18 and older, any sex, with High Grade Gliomas. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Gliomas are tumors that occur in all ages; they include the most common malign primary central nervous system tumors in developed countries. Gliomas are often aggressive, and their recommended treatment is surgical resection and chemoradiation. Complete tumor removal is challenging because of diffuse cell growth and the proximity of functionally critical tissues. Surgeons use 5-aminolevulinic acid (5-ALA) drug-induced fluorescence to visually detect tumor cells, which improves resection rates and delays tumor progression. Tumor cells are often left unnoticed because of visual obstacles or weak fluorescence, which may lead to local recurrence and reoperations. Surgical suction devices are used to remove cancerous tissues, but so far the suction aspirate tissues have not been routinely used in tissue detection. This multicenter controlled clinical trial investigates the clinical performance and outcomes of a new method for detecting tumor from the suction aspirates in near-real time based on 5-ALA induced fluorescence. The feedback from the aspirate tissue monitor (ATM) is expected to improve the identification of tumors, leading to fewer reoperations and better treatment outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06740097
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Kuopio University Hospital trials
Trials by the same sponsor.
- NCT06725433 — Nissen Versus Dor Hiatal Hernia Repair · NA · recruiting
- NCT06495268 — Healthy heaAring for Healthy Ageing: Data-driven Hearing Rehabilitation Intervention to Promote Healthy Hearing · NA · active not recruiting
- NCT06460363 — Transcranial Alternating Current Stimulation on Patients with Delirium and Critical Illness (DeliTACS) · NA · recruiting
- NCT05863624 — Open and Endoscopic Technique in Female Inguinal Hernia Repair. FemaleHernia · NA · not yet recruiting
- NCT06321133 — High Flow Nasal Cannula Weaning in Acute Bronchiolitis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06740097 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kuopio University Hospital
- Last refreshed: 18 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06740097.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing